Bristol Myers Squibb PE Ratio 2010-2022 | BMY

Current and historical p/e ratio for Bristol Myers Squibb (BMY) from 2010 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Bristol Myers Squibb PE ratio as of December 01, 2022 is 10.41.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Bristol Myers Squibb PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-12-01 80.88 26.35
2022-09-30 70.55 $3.07 22.98
2022-06-30 76.41 $3.01 25.39
2022-03-31 71.97 $2.82 25.52
2021-12-31 60.46 $3.12 19.38
2021-09-30 57.38 $-2.40 0.00
2021-06-30 63.79 $-2.27 0.00
2021-03-31 60.27 $-2.78 0.00
2020-12-31 58.76 $-4.01 0.00
2020-09-30 56.25 $-0.11 0.00
2020-06-30 54.44 $-0.10 0.00
2020-03-31 51.19 $0.81 63.20
2019-12-31 58.54 $2.19 26.73
2019-09-30 45.86 $3.47 13.22
2019-06-30 40.66 $3.80 10.70
2019-03-31 42.40 $3.16 13.42
2018-12-31 45.78 $3.03 15.11
2018-09-30 54.33 $0.88 61.74
2018-06-30 48.08 $0.23 209.06
2018-03-31 54.61 $0.56 97.51
2017-12-31 52.57 $0.59 89.09
2017-09-30 54.34 $2.54 21.40
2017-06-30 47.18 $2.75 17.16
2017-03-31 45.71 $2.88 15.87
2016-12-31 48.80 $2.65 18.42
2016-09-30 44.72 $2.04 21.92
2016-06-30 60.99 $1.74 35.05
2016-03-31 52.70 $0.97 54.33
2015-12-31 56.41 $0.97 58.16
2015-09-30 48.29 $1.06 45.55
2015-06-30 53.64 $1.07 50.13
2015-03-31 51.70 $1.35 38.29
2014-12-31 47.31 $1.20 39.43
2014-09-30 40.48 $1.63 24.83
2014-06-30 38.08 $1.62 23.51
2014-03-31 40.50 $1.74 23.28
2013-12-31 41.43 $1.55 26.73
2013-09-30 35.57 $1.67 21.30
2013-06-30 34.08 $0.82 41.56
2013-03-31 31.14 $0.88 35.39
2012-12-31 24.38 $1.15 21.20
2012-09-30 24.99 $1.09 22.93
2012-06-30 26.37 $2.08 12.68
2012-03-31 24.51 $2.22 11.04
2011-12-31 25.34 $2.15 11.79
2011-09-30 22.34 $1.93 11.57
2011-06-30 20.61 $1.92 10.74
2011-03-31 18.60 $1.93 9.64
2010-12-31 18.17 $1.79 10.15
2010-09-30 18.61 $5.57 3.34
2010-06-30 16.92 $5.50 3.08
2010-03-31 17.88 $5.46 3.28
2009-12-31 16.71 $5.35 3.12
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $170.688B $46.385B
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
Stock Name Country Market Cap PE Ratio
GSK (GSK) United Kingdom $70.345B 8.82
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.861B 0.00
Myovant Sciences (MYOV) United Kingdom $2.600B 0.00
Arcus Biosciences (RCUS) United States $2.547B 38.23
Biohaven (BHVN) United States $1.078B 0.00
Emergent Biosolutions (EBS) United States $0.614B 4.82
Zymeworks (ZYME) Canada $0.486B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.281B 0.00
Enzo Biochem (ENZ) United States $0.097B 0.00
SQZ Biotechnologies (SQZ) United States $0.074B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00